Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I feel the webinar with KOLs will greatly increase visibility for Todos and Tollovir/Tollovid.
Added 110K TOMDF and 600K AMBS shares this morning. First venture into AMBS but seems like a no-brainer considering they own 78M shares and seeing what's unfolding with Todos and Tollovir/Tollovid.
Exciting times ahead for both companies. Expecting some news soon for Amarantus and the path forward. GLTA
NEWS: Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics
New York, NY, and Tel Aviv, ISRAEL, Dec. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab has launched the “Test & Tollovid®” Holiday Package for the Atlanta area. The Holiday Package is priced at $329 and includes one (1) bottle of maximum strength Tollovid and one (1) at-home saliva sample collection kit to be returned in a prepaid overnight FedEx envelope for a COVID-19 PCR test. For faster test results, customers can drop samples off at the lab during business hours. To order or get further details regarding the Holiday Package please visit http://www.provistadx.com/holiday-package
https://investor.todosmedical.com/news-events/press-releases/detail/165/todos-medical-announces-test-tollovid-holiday
I fully expect the Biden administration to stick with Paxlovid since they've already publicly committed billions in funds to the drug, even before EUA is granted. They likely won't reverse course even if Tollovir is shown to be far superior. Also, I expect many of the politicians in the administration have a vested interest in Pfizer shares and won't change course for that reason as well.
I believe Todos will take much of the rest of the world market, just not the USA market. I believe Pfizer will rule here even with an inferior product. Beta format was superior to VHS in every aspect and was adopted in most of the world, but USA adopted VHS.
Unfortunately, if my expectations come true, we'll likely watch Covid deaths outside the USA plummet in the coming year, while USA trudges forward waving the Paxlovid flag as the answer. This administration seems very slow to change course as they "follow the science."
Fortunately, everyone on this board knows better and knows how to protect our families.
Gerald discusses supply and demand for the natural product in the recent Todos Medical Business Update Conference Call, and their plans to meet expected worldwide demand by formulating a chemical compound version of Tollovir that targets the same receptor site as the natural version. Lots of great info in the presentation and Q & A session afterwards.
https://audience.mysequire.com/webinar-view?webinar_id=6b97aec0-7ccb-4754-9a33-5c26d34d9597
Extended another 90 days. Nasdaq uplist planned for Q1 2022.
conversions mortorium lifting on 12/13/21
what will the noteholders do - renegotiate, extend or convert?
NEWS: Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, Dec. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the Company has entered into a new agreement with holders of its convertible notes that provides for a 90-day moratorium on conversion of those convertible notes and a restriction on sales of common shares owned by those noteholders (collectively the “New Lockup”). This New Lockup was entered into immediately after the expiry of a similar agreement on December 10, 2021 which was announced on September 24, 2021 (the “Old Lockup”).
“We are very pleased that we were able to come to a resolution on the restriction on Ordinary share sales into the market with our convertible debt holders such that there will be fixed number of shares outstanding as we head into an interim data readout of the Tollovir® Phase 2 clinical trial in hospitalized COVID-19 patients,” said Gerald E. Commissiong, President & CEO of Todos Medical. “We are seeing a significant ramp in COVID PCR and cPass neutralizing testing demand at our CLIA/CAP-certified lab Provista Diagnostics, while at the same time seeing sales increase for our dietary supplement products Tollovid® and Tollovid Daily™ that are the only products in the marketplace that have received 3CL protease inhibitor claims from the U.S. Food & Drug Administrations. Our recently announced European licensing and distribution partnership with T-Cell Protect Hellas S.A. for our Tollovid-branded products has already made a material impact on our revenue for the fourth quarter, and we are now expecting additional orders and distribution agreements to be established as demand for 3CL protease inhibitor products increases dramatically in the months ahead and we believe Todos can play a major role in supplying these products to meet that demand. We believe the fact that management was able to negotiate this New Lockup demonstrates the confidence these investors have in our plan and should also provide confidence to the marketplace in our ability to deliver on our promises, give the Company sufficient room to finalize key strategic transactions previously announced to unlock shareholder value and help facilitate the listing of our common shares on a national stock exchange in the months ahead.”
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
https://investor.todosmedical.com/news-events/press-releases/detail/163/todos-medical-enters-90-day-extension-of-agreement-with
Posting links from Twitter directly sometimes requires the reader to register on Twitter to dig down into the responses, and some here have no interest in registering an account. So while one might be a day or two late in reading Gerald's tweets, I do try to post everything relevant to Todos and have a system established to keep the posts in order by time posted and by topic.
Also, I find it easier to review his prior tweets here than digging through the Twitter feed. Sometimes a question is posted here that was already addressed in a prior tweet and I can refer the poster back to that specific post.
Some of the questions you ask are addressed by Gerald in several recent interviews or presentations. Highly recommended viewing if you haven't watched, or perhaps watch again... always little nuggests there one misses with a single viewing. There's a ton of information to digest.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167072537
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166904622
Regarding revenue, at one time monthly revenue was being reported, but for most of this year Gerald has backed off that practice and now reports revenues only in the quarterly filings. The company had a client who failed to pay for reagents and equipment and I believe he got a lot of heat from shareholders over that, so no more revenue figures in press releases or presentations. We'll have to wait for quarterly filings to see the numbers. Legally, that's all any company is required to report. We as shareholders want more and expect more frequent reporting, but from a company standpoint it can present perceptions of wrongdoing when the quarterly numbers don't align perfectly with the interim-reported numbers.
Share Structure Update - 12/10/21
1,500,000 shares issued since last update on 12/3/21.
https://www.otcmarkets.com/stock/TOMDF/security
It was this part of the news release that got me thinking...
The presentation will be delivered by Todos Medical’s CEO Gerald Commissiong, who is expected to map out the corporate strategy for Tollovir approval in multiple jurisdictions
Anyone think this might be the announcement of Tollovir phase 2 trial interim data?
NEWS: Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
https://investor.todosmedical.com/news-events/press-releases/detail/162/todos-medical-interview-and-presentation-on-benzingas-all
New York, NY, and Tel Aviv, ISRAEL, Dec. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical will be interviewed live on Benzinga’s All Access Conference held on December 14, 2021 at 10:20 AM Eastern Standard Time. The presentation will be delivered by Todos Medical’s CEO Gerald Commissiong, who is expected to map out the corporate strategy for Tollovir approval in multiple jurisdictions as well as highlight the advancements in the testing business.
The following are details for the conference:
Event: Benzinga All Access Show
Date: December 14, 2021
Location: On-Line
Time: 10:20 – 10:40 AM / Eastern Standard Time
This live, interactive online event with Benzinga Host Spencer Israel will give existing shareholders and the investment community unique insight into the company as the CEO Gerald Commissiong lays out the Company’s plans for the future.
To view the presentation, please visit
I have wondered about that as well. If someone has a subscription would that person have priority with any new stock arriving over someone who placed a single bottle order? Might be worth investigating buying a case from Alibaba. That's probably a better option anyway for someone who is purchasing for several family members, as it would lower the cost per bottle.
Sorry, I missed the part where you said you had previously ordered Tollovid Daily. I looked at the emails I received where the discount code was offered and there was nothing about initial purchase only. Also, I have previously ordered both products and both codes still worked for me, but I didn't complete the order beyond the screen where the discount was added. Did your code get rejected later in the purchase process?
That's odd, because I just went to the site and tried both discount codes below I have previously received from Todos and both codes worked for Tollovid and Tollovid Daily. Neither code works if you select the subscription price (already discounted), but work for the single order.
10% discount with code IMMUNITY10
15% discount with code TOLLO15
The biggest plus in today's presentation is the Todos Medical sign on the wall had no visible Scotch tape. It looks like Gerald took my advice and that of others who contacted him and put the tape behind the sign and not on the corners or edge. It's a little thing, but little things matter when you're trying to make a professional presentation.
Great presentation today. Very good question and answer session, just wish there was more time for it. Gerald is proving himself to be an expert with his knowldge of the Covid field and a strong advocate for the company and their goals. And there have been several questions in the last few interviews regarding Amarantus and I believe this is providing him an opportunity to demonstrate he understands the mistakes he made there and how he's structuring Todos to not go down that same path.
Shares at this price are a gift. I plan to buy more as funds are available, and some Amarantus shares as well.
Personally, as a shareholder, I would take advantage of any discount the company offered me, and invest the savings back into more Todos shares.
So far I've purchased 3 bottles of Tollovid (2 for family members, 1 for myself) and 1 bottle of Tollovid Daily for myself, and have used the discount code for every purchase. Whether or not the company continues to offer discounts will not affect my decision to purchase the product, but discounts are a standard marketing tactic in virtually every product for sale online these days and I'm sure the company has factored this into their revenue projections.
It will be interesting to see how worldwide demand for Tollovid unfolds. GLTA
Proactive News: Todos Medical says its CLIA/CAP lab Provista Diagnostics enters two new coronavirus PCR testing reference lab contracts
https://www.proactiveinvestors.com/companies/news/968483/todos-medical-says-its-clia-cap-lab-provista-diagnostics-enters-two-new-coronavirus-pcr-testing-reference-lab-contracts-968483.html
I will try. Depends on work demands. But I did pick up another 28K shares today.
The Emerging Growth Conference is tomorrow, December 8, not today.
NEWS: Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
• Combined testing from two contracts averages 1,000 PCR samples per day
• Testing potential for the two contracts could ramp up to 5,000 PCR samples per day
New York, NY, Alpharetta, GA and Tel Aviv, ISRAEL, Dec. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP lab Provista Diagnostics has won two (2) new reference lab testing contracts from laboratories collecting samples in Georgia and New Jersey. In the last two weeks both labs referring have experienced a marked uptick in testing demand, primarily from schools, that has caused them to exceed their small testing capacity and required them to identify additional testing capacity available to meet their needs, making them ideal lab clients for Provista. Provista Diagnostics is Todos Medical’s wholly-owned CLIA/CAP certified lab that offers comprehensive, fast, automated COVID-19 testing solutions that help referring labs keep their clients by allowing them to deliver fast turnaround time (TAT) at scale.
“These reference lab contract wins continue to validate our strategy of building COVID-19 testing capacity in preparation for increasing institutional demand,” said Gerald Commissiong, CEO of Todos Medical, Provista’s parent company. “COVID-19 is not disappearing anytime soon. The Omicron variant has already dramatically increased the demand for fast turnaround times worldwide due to increased demands by governments to shorten the window in which a false negative result could allow travelers to import cases. When you add to this pending or already-imposed vaccination mandates that almost all have a universal opt-out with some form of testing, we expect a significant increase in COVID-19 testing demand will hit the market, and we are already seeing signs of that as evidenced by these two reference lab agreements. Given that it appears the Omicron variant is highly transmissible even among the fully vaccinated, as evidenced by the super spreader event at a restaurant in the Netherlands, we expect that the vaccine mandate will evolve into a testing mandate because even the vaccinated are now high-risk of contracting and spreading the virus. While we expect the vaccines to maintain their efficacy in preventing hospitalization and death, the fact that the virus can be spread among the vaccinated likely significantly increases the risk for Long COVID given that emerging data suggests Long COVID potentially remains a significant risk independent of vaccination status. With this backdrop, the most prudent course of action is to implement widespread testing, and we see policymakers being forced to move in that direction regardless of vaccination status. While serial rapid testing does appear to be an effective tool in identifying cases, in the absence of widespread serial use, only the PCR test should be used to certify infection status. Given what we are hearing from US policymakers, we do not expect rapid antigen tests to be made widely available in the United States, and so PCR testing will dominate.”
Provista currently has the automation setup and in place to conduct over 20,000 COVID-19 PCR tests per day. The lab also has the automation in place to conduct over 1,500 cPass semi-quantitative neutralizing antibody tests per day, over 5,000 COVID variant tests per day (including testing for the Omicron variant that is being implemented now by PCR variant kit) and over 5,000 respiratory panel tests per day.
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com. For referring labs interested in the COVID-19 PCR, variant, cPass neutralizing antibody body and/or respiratory panel testing services Provista offers, please email Sr. Director of Business Development James Doherty at dohertyj@provistadx.com for further information.
Agreed. In a previous video the presence of tape was not so clear and might have been part of the background pattern, as it appeared only on a single corner. In today's video it was clear there were 3 distinct pieces of tape used. Makes it look like Gerald arrived, taped up the sign, sat down to conduct the interview, stood up and took down the sign, and exited to make room for the next person on the interview list. Just looks rushed and unprofessional.
I emailed him and let him know how it distracts from his message (which was great) and gives the impression of a cheap company to newcomers and existing shareholders alike. Attention to little things goes a long way. It's almost as bad as having a sign that reads Todos Medicle or something similar. What kind of impression would that make on a potential shareholder?
You can't patent a plant. But you can patent the formulation of specific extracts (and there are multiple ones in Tollovir) and the target mechanism for the drug. Gerald stated in the CC that even though Pfizer was employing the same 3CL protease inhibition method of stopping viral replication, it's not the same target as Tollovir.